Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Persisting Effects of Psilocybin
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 13
- Registration Number
- NCT02971605
- Locations
- ๐บ๐ธ
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Joshua Woolley
- Target Recruit Count
- 30
- Registration Number
- NCT02950467
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 12
- Registration Number
- NCT02421263
- Locations
- ๐บ๐ธ
NYU Langone Medical Center/Tisch Hospital, New York, New York, United States
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 24
- Registration Number
- NCT02243813
- Locations
- ๐บ๐ธ
Behavioral Biology Research Center, Johns Hopkins Bayview, Baltimore, Maryland, United States
UW Psilocybin Pharmacokinetics Study
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 12
- Registration Number
- NCT02163707
- Locations
- ๐บ๐ธ
University of Wisconsin, School of Pharmacy, Madison, Wisconsin, United States
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
- Conditions
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 95
- Registration Number
- NCT02061293
- Locations
- ๐บ๐ธ
Clinical and Translational Science Institute, NYU Langone Medical Center, New York, New York, United States
๐บ๐ธUniversity of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Psilocybin-facilitated Treatment for Cocaine Use
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 40
- Registration Number
- NCT02037126
- Locations
- ๐บ๐ธ
UAB Outpatient Clinical Research Unit, Birmingham, Alabama, United States
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT01988311
- Locations
- ๐บ๐ธ
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 10
- Registration Number
- NCT01534494
- Locations
- ๐บ๐ธ
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
- Locations
- ๐บ๐ธ
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.